Last update: 23.07.2024 01:04 (GMT+3)

Purchase of Tallinn Pharmaceutical Plant: the effect of the deal on financial performance in 2003

28.04.2003, Grindeks, RIG

"Grindeks" expects that in 2003 revenues from participation in TPP
will be twice as high as actual revenues from participation in the
company in 2002. The forecast is based on two assumptions: the expected
increase of TPP net profit and increase of "Grindeks" ownership
interest in TPP. It is expected that the received profit will be in
proportion to the ownership interest: 12.34% on the top of the profit
received if "Grindeks" had retained the holding at 64.14% level. The
respective figures for 2002 are presented in the table:

+-------------------------------------------+---------------------------------------+-----------------+
| |2002 (actual) |2003 (planned) |
|TPP net profit |4,995,114 EEK |7,923,059 EEK |
| |199,804 LVL |316,922 LVL |
|Grindeks ownership interest % |54.96% (from the beginning of the year)|76.48% |
| |up to 64.14% (from 07.11.02) |(from 11.04.2003)|
|Grindeks revenues from participation at TPP|104,969 LVL |6,059,566 EEK |
| | |242,382 LVL |
+-------------------------------------------+---------------------------------------+-----------------+


The expected economic effect from the deal
The rationale behind the deal is "Grindeks" strategy to maximise
profits via a more efficient use of resources, at the same time
offering a wide and competitive range of products. This is achieved by
combining the resources of both companies and specialising in
production. Acquisition of TPP shares is based on the intention to
integrate TPP in the parent company "Grindeks" , and establishes the
conditions for implementing the above business strategy, also
emphasising a less complicated company management. The intent is to
fully integrate TPP and make it a specialised company. Already now TPP
speciality is the manufacturing of ointments in compliance with Good
Production Practice. The economic justification for acquisition of TPP
shares is based on forecasts about TPP profit dynamics, consequently,
increased "Grindeks" revenues from capital participation.
Long-term strategy envisages synergies derived from establishing a
holding of Baltic pharmaceutical companies that would be based on
mutually advantageous co-operation between Baltic pharmaceutical
companies. TPP integration is an evidence of concrete activities to
attain the objective.
The first steps towards Baltic pharmaceutical company enhanced
co-operation were made in 1998 when "Grindeks" acquired control
interest in TPP. Currently further co-operation possibilities with
other Baltic pharmaceutical companies are assessed. A feasibility study
of the potential co-operation will be completed in autumn of this year.
At that time the development perspectives of Baltic pharmaceutical
holding would be outlined.

Tradable Assets

Shares
Bonds
Funds

Market information

Statistics
Trading
Indexes
Auctions

Market Regulation

Rules and Regulations
Surveillance

Get Started

For Companies
For Investors
For Brokers/Members
For First North Advisers

News

Nasdaq News
Issuer News
Calendar

About Us

Nasdaq Baltic Market
Offices